According to Enzo Biochem's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.52015. At the end of 2024 the company had a P/S ratio of 5.01.
Year | P/S ratio | Change |
---|---|---|
2024 | 5.01 | -14.14% |
2023 | 5.83 | 390.31% |
2022 | 1.19 | -17.54% |
2021 | 1.44 | 39.78% |
2020 | 1.03 | -44.98% |
2019 | 1.88 | 16.24% |
2018 | 1.61 | -62.15% |
2017 | 4.26 | 56.87% |
2016 | 2.72 | 55.35% |
2015 | 1.75 | -27.63% |
2014 | 2.42 | 116.86% |
2013 | 1.11 | 46.1% |
2012 | 0.7630 | -29.41% |
2011 | 1.08 | -35.88% |
2010 | 1.69 | -24.3% |
2009 | 2.23 | -18.02% |
2008 | 2.72 | -62.18% |
2007 | 7.18 | -37.61% |
2006 | 11.5 | 13.43% |
2005 | 10.1 | -26.26% |
2004 | 13.8 | 11.74% |
2003 | 12.3 | 72.29% |
2002 | 7.15 | -27.11% |
2001 | 9.81 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Quest Diagnostics
DGX | 1.51 | -66.56% | ๐บ๐ธ USA |
LabCorp LH | 1.30 | -71.23% | ๐บ๐ธ USA |
RadNet RDNT | 2.17 | -51.98% | ๐บ๐ธ USA |
Psychemedics PMD | 0.6726 | -85.12% | ๐บ๐ธ USA |
NeoGenomics
NEO | 2.97 | -34.27% | ๐บ๐ธ USA |
Qiagen QGEN | 4.45 | -1.65% | ๐ณ๐ฑ Netherlands |